Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply

Loading news article.

Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply | WAPE

Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply

Article summary

Related companies

Comments —